Mitotic kinesin inhibitors

Details for Australian Patent Application No. 2004266232 (hide)

Owner Merck & Co., Inc.

Inventors Cox, Christopher D.; Hartman, George D.; Coleman, Paul J.; Garbaccio, Robert M.

Agent Spruson & Ferguson

Pub. Number AU-B-2004266232

PCT Pub. Number WO2005/019206

Priority 60/495,637 15.08.03 US; 60/563,580 19.04.04 US

Filing date 11 August 2004

Wipo publication date 3 March 2005

Acceptance publication date 3 July 2008

International Classifications

A61P 35/00 (2006.01) Antineoplastic agents

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

2 March 2006 PCT application entered the National Phase

  PCT publication WO2005/019206 Priority application(s): WO2005/019206

3 July 2008 Application Accepted

  Published as AU-B-2004266232

30 October 2008 Standard Patent Sealed

21 January 2010 Amendment Made

  The nature of the amendment is: Amend the patentee name from Merck & Co., Inc. to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004266233-Melanin concentrating hormone receptor antagonist

2004266228-Melanin concentrating hormone receptor antagonists